.jpg%3Ftrim%3D0%2C50%2C0%2C50%26width%3D1200%26height%3D800%26crop%3D1200%3A800&w=3840&q=100)
Reporter from MyPillow guy's network asks White House the secret behind Trump looking ‘healthier than ever before'
Absolutely teeing up her question to Leavitt, the Lindell TV 'reporter' wondered if the White House would be able to share Donald Trump's secret 'fitness plan' because the 78-year-old president looks 'healthier than ever before' and better than when he first began running for political office.
The fawning 'question' to wrap up Friday's presser — which largely focused on the continued impacts of Trump's chaotic tariffs, the upcoming talks with Iran, and the Supreme Court ruling the administration must 'facilitate' the return of a wrongly deported man — is yet another example of how this administration is reshaping press coverage within the White House.
The president was scheduled to undergo his yearly physical exam at Walter Reed on Friday, which would be his first comprehensive examination in over 18 months. Despite being the oldest president to be sworn into office for a new term, Trump — who spent much of the past four years assailing his former President Joe Biden's mental fitness — is reportedly not expected to take a cognitive test during this exam.
Castronuova, who asked Leavitt two days ago if Trump was 'disappointed' with conservative Supreme Court Justice Amy Coney Barrett, took the opportunity to close out this latest press briefing by gushing over Trump's physical appearance.
'Will you guys also consider releasing the president's fitness plan?' Castronuova asked after Leavitt pledged that the White House would quickly share the results from Trump's medical exam.
'He actually looks healthier than ever before,' the Lindell TV White House correspondent continued. 'Healthier than he looked eight years ago, and I'm sure everyone in this room can agree. Is he working out with Bobby Kennedy, and is he eating less McDonald's?'
Castronuova seemed to be referencing Health and Human Services Director Robert F. Kennedy's 'Make America Healthy Again' agenda, which would target processed food — among other things. At the same time, the McDonald's-loving president infamously forced Kennedy to pose for a photo alongside a feast from the fast food joint, prompting the Trump official to later testify that he's not coming after your 'cheeseburger and Diet Coke, which my boss loves.'
'I can confirm that the president is in very good shape as you see on your daily basis here,' a pleased and smiling Leavitt responded to Castronuova. 'And in that vein, thank god it's Friday. It's been a long, busy week at the White House. We will see you all Monday. We will release the results of that report as soon as we can.'
Since Trump's return to office, the administration has seized power from the White House Correspondents' Association on the press pool rotation and is threatening to take over seating assignments in the briefing room. Additionally, Leavitt has elevated so-called 'new media' voices in the pressers — which has included a number of MAGA loyalists from fringe outlets.
Castronuova, who was a trainer on season 11 of The Biggest Loser, made headlines last year when she sued the New York State Board of Elections for allegedly preventing her name from being written in as a Republican challenger to Sen. Kirsten Gillibrand (D-NY). She was initially kept off the GOP ballot when party leaders decided to forego a Republican primary.
Earlier this year, she was hired to be the chief White House correspondent for Lindell TV, the MAGA digital channel run by the Trump-boosting pillow magnate who's been facing existential financial and legal peril in recent months.
'We're absolutely thrilled to welcome Cara Castronuova to the team. Our viewers will get an up-close and personal look at White House press coverage like they've never seen before,' Lindell said in a statement about Castronuava's hiring. 'She will provide the kind of hard-hitting, competent reporting that pulls no punches while she delivers unbiased breaking news stories from the White House that other networks refuse to report.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
24 minutes ago
- Daily Mail
Poland scrambles war planes as Russia unleashes hypersonic missile barrage and strikes Ukrainian city near NATO border - as Kremlin calls West's peace talks 'a road to no-where'
Poland said on Thursday that warplanes have been scrambled to protect its airspace as Russia staged its biggest hypersonic missile barrage on Ukraine since Putin met Trump last Friday. The Operational Command of the Polish Armed Forces said on X: 'In connection with the activity of long-range aviation of the Russian Federation, conducting strikes on Ukrainian territory... aircraft of the Polish Air Force and allied aviation are operating in Polish airspace.' Russian attacks on western Ukraine killed one person and wounded multiple others, officials in the country said Thursday as diplomatic efforts to end the three-year war grind on. Moscow and Kyiv have kept up their aerial attacks on each other as world leaders including US President Donald Trump push for a ceasefire. 'One person was killed and two were wounded as a result of the combined UAV and cruise missile strike in Lviv,' said Maksym Kozytskyi, head of the regional military administration. 'Dozens of residential buildings were damaged,' he added in a Telegram post. Russian fire also wounded 12 people in the city of Mukachevo, near the border with Hungary and Slovakia, the city council said. 'Five patients are being treated in the hospital, and one more was transferred to the regional hospital,' the council wrote on Facebook. In Lutsk, Mayor Igor Polishchuk reported 'an enemy attack that was conducted by UAVs and missiles'. 'As of this moment there are no injuries or fatalities,' he said. Meanwhile, Russia's defence ministry said it destroyed '49 Ukrainian aircraft-type unmanned aerial vehicles' across multiple regions. The ministry did not detail any casualties or damage. The latest cross-border fire follows Trump's flurry of diplomacy this month aimed at ending the war. The US president
Spectator
34 minutes ago
- Spectator
Why your weight loss jab is ballooning in price
'A friend of mine who's slightly overweight, to put it mildly, went to a drug store in London,' Donald Trump said aboard Air Force One. Earlier he had told reporters: 'He was able to get one of the fat shots. 'I just paid $88 and in New York I paid $1,300. What the hell is going on? It's the same box, made in the same plant, by the same company.'' You can see why the dealmaker-in-chief was irked. And when Trump is irked, someone usually pays the price. In May, the President signed an executive order for 'most-favoured-nation prescription drug pricing for American patients'. It was a warning to drug companies, as well as other countries, that Americans were tired of paying nearly three times more for the same medicines as patients abroad. The US is home to less than 5 per cent of the world's population and yet American consumers account for almost three-quarters of global pharmaceutical profits, because manufacturers heavily discount their drugs overseas and make up the difference by inflating prices in the States. As the President puts it, 'freeloading' foreign customers 'get a free ride'. He's not wrong. But while Trump may get his wish in stopping overseas health systems from getting cheaper deals, it's not obvious that profit–making companies will cut their prices in America. The more likely response is that they'll raise them everywhere else. Eli Lilly, the American pharmaceutical giant behind the weight-loss jab Mounjaro, has announced that from September the recommended retail price of its strongest monthly dose in Britain will leap from £122 to £330 – inflation of more than 170 per cent. The company knows the NHS won't actually pay that much: it has already negotiated substantial discounts for the doses it prescribes. But by hiking the list price on the highest dose (which relatively few patients use), while cutting the private deals on lower doses, Lilly can appease Washington and protect its market at the same time. For now, anyway. But demand is picking up. In Britain, around 1.5 million people are already on weight-loss drugs, with 90 per cent paying out of pocket. Most take Mounjaro, while a smaller number are on Wegovy, the sister drug to Ozempic. Novo Nordisk, the Danish manufacturer of Wegovy, has agreed to keep its UK price low for the time being. But costs will eventually be driven up for Wegovy users too if Mounjaro users, faced with a much bigger bill, convert to Wegovy en masse, squeezing supply. Fat loss clinics are already seeing a 500 to 600 per cent increase in Brits switching to Wegovy, which – come September – will cost half the price of Mounjaro. Trump's war on drug pricing will affect other areas of British medicine too. Weight-loss jabs have become the symbol of American pharma – and its many excesses – but they are by no means the only miracle drug we get for cheap. Take Casgevy, a US-made gene therapy that can treat the blood conditions beta thalassemia and sickle cell disease. One dose costs more than £1.6 million at list price. Thanks to its clout as the country's single dominant buyer, the NHS has secured a confidential – though significant – discount. Casgevy's eye-watering price is easy to justify: therapies at the frontier of medicine cost billions to develop. British politicians love to remind us that the UK is a world leader in life sciences, and in many ways that's true, but it's the US that is funding nearly half of all global life-sciences research and development. Trump, in typical fashion, wants the credit – or at least cheaper price tags. But drug makers won't cut their profits; they'll shrink everyone else's discounts. The NHS's bargaining power may shield patients for a time, but price rises are coming. UK officials know it, too. Even before the latest hikes on the fat jabs, government papers released alongside the US-UK trade talks in May noted that the NHS would look at the concerns of the President. No prime minister or health secretary could openly sign up to higher drug costs borne by the NHS, but they knew Trump had not finished going after what he considers to be unfair trade practice. The uncomfortable truth for the British is that as much as we mock US healthcare as extortionate and venerate our NHS as sacred, we live off America's excess. The American healthcare system is Britain's greatest scapegoat: it's absurdly expensive, highly inefficient and still doesn't manage to provide universal coverage. Indeed, it's the only healthcare system in the developed world that can distract from just how poor our own is: a 'National Health Service' that falls short of practically every standard and target set for it. The NHS survives only because we ignore its outcomes. Measure after measure shows that plenty of people are being failed by an expensive, yet decaying system. Britain spends around £36 billion a year on pharmaceuticals, £19 billion of that coming from the NHS. Medicines are already the health service's second-biggest expense after staff. But that number would be a lot higher without America. Britain may be world-class in medical research, but we spend just 0.3 per cent of GDP on drug research and development, compared with America's 0.8 per cent. American money makes Britain's drug research possible. And for years, until drugs lose their patent, Americans pay exorbitant costs which subsidise the NHS's bargain prices. This model which so annoys Trump perhaps helps explain why the NHS continues to enjoy such widespread public support, despite its many failures. We'll tolerate months-long waiting lists, worse survival chances and outdated facilities if we have cheap or 'free' access to life-changing medicines. But will we put up with the broken system if we have to start paying a fair whack for drugs, either directly at the pharmacy counter or indirectly through the increased taxation that would be needed to fund them? The government won't give up our bargain pricing without a fight. Quietly, and at significant political cost, health officials will roll out a new strategy. We're never going to pay American prices for drugs – the 'free at the point of use' funding model simply could not afford it. Instead, we'll try to make our research environment so attractive to manufacturers that they'll reward us by maintaining drug discounts. That's the real motivation behind Wes Streeting's planned reforms for the NHS, which are championed by his supporters as a way to improve the patient experience and attacked by his critics as a covert means of privatising the health service. Take the single patient record, which NHS England says will give 'every part of the NHS a full picture of the patient'. Perhaps – but it will also make it far easier to identify people for clinical trials and medical research. Look at the partnership between the Wellcome Trust and the government to create a £600 million health data research service. The stated aim is to 'simplify access to health data and speed up research'. But it also makes Britain an attractive place for pharmaceutical companies. The offer is simple: we'll make it as easy and welcoming as possible for you to do your research here, you've just got to keep paying for it. This is the part British politicians never want to say out loud, especially when it comes to healthcare: someone, somewhere, is always paying for it. Drugs aren't 'cheap'. The NHS isn't 'free'. There are always trade-offs: either higher prices, longer wait times, or uncomfortable deals and data swaps with Big Medicine. No matter how you spin it, Britain's 'free ride' is coming to an end.
The Herald Scotland
34 minutes ago
- The Herald Scotland
ODNI to slash costs by 40% as part of big intelligence agency overhaul
The move is expected to save taxpayers over $700 million annually and better enable ODNI to focus on "fulfilling its critical role of serving as the central hub for intelligence integration, strategic guidance, and oversight over the Intelligence Community," said the late afternoon news release. "Over the last 20 years, ODNI has become bloated and inefficient, and the intelligence community is rife with abuse of power, unauthorized leaks of classified intelligence, and politicized weaponization of intelligence," Gabbard said in the release. "ODNI and the IC must make serious changes to fulfill its responsibility to the American people and the U.S. Constitution by focusing on our core mission: find the truth and provide objective, unbiased, timely intelligence to the President and policymakers." Intel agency long a focus of Trump's ire The ODNI was established in April 2005 after the blue ribbon 9/11 Commission exposed systemic failures across the intelligence community. Its purpose was to integrate intelligence from - and provide oversight over - all of the various intel elements of the U.S. government, including the CIA, the eavesdropping National Security Agency and several military intelligence agencies. Trump has frequently attacked the agency as politicized against him, and has vowed, along with Gabbard, to downsize and restructure it. Sen. Tom Cotton of Arkansas, the Republican chairman of the Senate Intelligence Committee, sponsored legislation June 27 to cap the ODNI staff at 650, down from what he said was about 1,600, to eliminate certain reporting requirements and to transfer some key counterintelligence and counterproliferation responsibilities back to the CIA. The ODNI news release said ODNI 2.0 will eliminate redundant missions, functions and personnel, and make "critical investments in areas that support the President's national intelligence priorities." It will also expose what President Donald Trump and Gabbard have called the politicization and weaponization of intelligence, and hold "bad actors accountable." Going after those involved in 'Russia Hoax' That effort expands on a campaign that Gabbard already has launched to investigate Democrats in the Obama and Biden administrations that she claims falsified intelligence to concoct a false "Russia Hoax" about Trump complicity in the Kremlin's interference in the 2016 election. Multiple investigations and reports, including a bipartisan effort by the Senate Intelligence Committee, have found that Russia did indeed meddle in the 2016 election to help Trump defeat his Democratic rival Hillary Clinton. One key target of the new overhaul is the ODNI's efforts to call out Russia for continued interference in U.S. elections, including the 2024 president campaign, through its multi-agency Foreign Malign Influence Center or FMIC. Refocusing FMIC's mission will save American taxpayers at least $7 million per year, according to an ODNI 2.0 fact sheet released by the spy agency. It did not provide details of what that refocus will entail, or a similar plan to overhaul the ODNI's National Counterproliferation and Biosecurity Center (NCBC) and its Cyber Threat Intelligence Integration Center (CTIIC). "ODNI's hyper-focus on election-related work notably began in 2017, immediately following the publication of the manufactured Intelligence Community Assessment (ICA) falsely alleging Putin 'aspired' to help President Trump win the 2016 election," the fact sheet said. 'No confidence' Gabbard is right person to conduct ODNI overhaul Virginia Sen. Mark Warner, the ranking Democrat and vice chair of the Senate Intelligence Committee, acknowledged in a statement that there is broad, bipartisan agreement that the ODNI "is in need of thoughtful reform." The current Intelligence Authorization Act directs Gabbard to submit a plan to Congress outlining her proposed changes, Warner said, "and we will carefully review her proposals and conduct rigorous oversight to ensure any reforms strengthen, not weaken, our national security." "But given Director Gabbard's track record of politicizing intelligence - including her decision just yesterday to revoke security clearances from career national security officials - I have no confidence that she is the right person to carry out this weighty responsibility," Warner said. Gabbard announced Aug. 19 that Trump had directed her office to revoke security clearances from 37 former intelligence officials for "politicizing and manipulating intelligence." Most were affiliated with the Biden and Obama administrations or signatories to public protests of Trump's policies. Warner and other Democrats have also criticized Gabbard for forming a task force that amounts to nothing less than a "witch hunt" for officers and analysts within the 18 U.S. intelligence agencies it deems disloyal to Trump. Cotton, the committee chair, called ODNI 2.0 "an important step to return the department to its original size, scope and mission." "I look forward to working with @DNIGabbard to implement these reforms and ensuring the IC focuses on its core mission: stealing secrets from our adversaries," Cotton said in a post on X. This story has been updated to include additional information. Josh Meyer is USA TODAY's Domestic Security Correspondent. You can reach him by email at jmeyer@ Follow him on X at @JoshMeyerDC and Bluesky at @
